What We Do

The International Vaccine Access Center accelerates equitable and sustainable access to vaccines in low- and middle-income countries by generating, synthesizing, and using evidence to inform decision making and action.
Our Approach Blends
  • Rigorous science
  • Productive partnership
  • Clear communication
  • Capacity building and training

Our Practice Areas

Country Support

Based on demand from country leaders and health agencies around the world, we provide independent policy advice, support country vaccine decision-making and governance, and connect partners to accelerate progress toward health and development goals.

Coverage & Equity

To improve equitable immunization within and between countries, we help countries better measure vaccine coverage, interpret results for action, and boost demand for vaccination using novel strategies.

Major studies evaluate the feasibility of using blood samples to identify gaps in immunity and implement mobile-based reminder systems, two approaches that could be adopted by governments to strengthen vaccination programs and protect all children.

Disease Epidemiology

To inform and improve prevention and control strategies, we manage large clinical studies and surveillance networks. We also quantify the amount of disease in countries and globally via mathematical models constructed with an understanding of population-level epidemiology, health system, and policy contexts.

Economics & Finance

To support investment and funding decisions, we quantify the cost of illness from diseases and determine the economic return on investment of vaccine use. We also help countries identify and address financing and affordability challenges.

Impact Evaluation

To inform policy & investments, we evaluate how vaccines reduce the spread of disease and create other value post introduction and over time.

Operations Research

To support the introduction of new vaccines and improvements in coverage, we analyze the programmatic and logistical implications of policy choices, such as variations in shipping, packaging, and other operational decisions that affect cost and health impact. Digital tools aid countries in designing, planning, and improving supply chains.

Policy Engagement

As a leading contributor to global immunization policy, we synthesize & present evidence to build consensus, inform strategy and support policy development. Members of IVAC’s leadership serve on the WHO Strategic Advisory Group of Experts (SAGE) and on several WHO working groups.

Technical Advocacy

To advance evidence-based policy, we support technically driven efforts, led by global and in-country partners, to understand the value of vaccines. We develop compendiums of published evidence, formulate messaging, and develop advocacy materials. We also build and manage coalitions and networks of scientists and other health advocates.

Antibiotics for Children With Severe Diarrhoea (ABCD)

The Antibiotics for Children With Severe Diarrhoea (ABCD) trial project led by WHO is a multi-site randomized, double-bind, placebo-controlled clinical trial attempting to evaluate the ability of an antibiotic (azithromycin) in reducing mortality within 90 days of the acute diarrhoeal episode and improve nutritional status over the same period.

Read More >

Baseline Assessment for Streptococcus pneumoniae of India Serotypes (BASIS)

BASIS  is a partnership led by the Johns Hopkins Bloomberg School of Public Health International Vaccine Access Center (IVAC), in collaboration with key Indian institutions, and is designed to establish a robust baseline estimate of pneumococcal serotype distribution prior to the introduction of PCV.

Read More >

Highly Extensible Resource Modeling Event-Driven Supply Chains (HERMES)

HERMES (Highly Extensible Resource for Modeling Event-Driven Supply Chains) allows the user to create detailed simulation models of vaccine supply chains.

Read More >

Impact of measles rubella vaccination campaign on population immunity in India

Policy makers may be better able to evaluate the progress of measles elimination and rubella control programs by understanding population immunity through large-scale serological surveys. This is a collaborative study led by the Indian Council of Medical Research.

Read More >

Indian Network for Streptococcus pneumoniae  and PCV Impact Research (INSPIRE)

This study will establish and maintain a surveillance network to measure the impact of routine infant vaccination with PCV on serotypes causing invasive pneumococcal disease among young children under 5 years of age in India.

Read More >